Objective In this study,we aimed to determine the incidence of adverse drug reactions(ADRs)of atezolizumab,identify ADR signals that are significantly related to atezolizumab,and provide a reference for the rational u...Objective In this study,we aimed to determine the incidence of adverse drug reactions(ADRs)of atezolizumab,identify ADR signals that are significantly related to atezolizumab,and provide a reference for the rational use of atezolizumab in the clinic through the statistical analysis of its adverse drug events(ADEs)reported in the American Food and Drug Administration(FDA)Adverse Event Reporting System(FAERS)database.Methods In total,4796 cases of atezolizumab ADEs reported in the American FAERS database from 2017 to 2019 were retrospectively analyzed.Results The top three ADEs were febrile neutropenia(3.7%),anemia(2.9%),and acute renal failure(2.3%).In addition,the incidence rates of some ADEs were significantly different according to sex and age.The systematic organ classification of atezolizumab ADEs involved 32 systems,among which the top three were blood and lymphatic system disorders(585 cases,12.2%),gastrointestinal disorders(433 cases,9.0%),and infections and infestations(401 cases,8.4%).The reporting odds ratio(ROR)method was used to detect the ADR signals of atezolizumab.The ROR(95%confidence interval)of the top ADE,febrile neutropenia,was 39.236(33.757–45.604).In addition,we found 121 cases of complications associated with immune-related ADEs.Conclusion The ADRs of atezolizumab reported in the FAERS database were consistent with those mentioned in the instructions for atezolizumab use,suggesting that atezolizumab has an acceptable and controllable drug effect.展开更多
目的分析与探讨达托霉素所致药品不良反应的发生特点及规律,为临床合理用药提供参考。方法检索万方、知网、维普、Web of Science、PubMed等数据库,收集达托霉素所致药品不良反应的相关文献,并进行统计与分析。结果共检索到59篇达托霉...目的分析与探讨达托霉素所致药品不良反应的发生特点及规律,为临床合理用药提供参考。方法检索万方、知网、维普、Web of Science、PubMed等数据库,收集达托霉素所致药品不良反应的相关文献,并进行统计与分析。结果共检索到59篇达托霉素所致的药品不良反应案例报道,以男性患者为主(70.83%),平均年龄为(61.5±14.3)岁,中位年龄(四分位数范围)为61(53.0~70.2)岁,多数为中老年患者;达托霉素多用于治疗骨、关节感染(61.11%);用药后药品不良反应发生的时间跨度较大,累及呼吸系统的不良反应最为常见(46.11%),其中以嗜酸性粒细胞肺炎为主。结论临床应用达托霉素时,医护人员应警惕相关药品不良反应的发生,药师应针对性地加强用药监护及药品不良反应干预,确保患者用药安全。展开更多
文摘Objective In this study,we aimed to determine the incidence of adverse drug reactions(ADRs)of atezolizumab,identify ADR signals that are significantly related to atezolizumab,and provide a reference for the rational use of atezolizumab in the clinic through the statistical analysis of its adverse drug events(ADEs)reported in the American Food and Drug Administration(FDA)Adverse Event Reporting System(FAERS)database.Methods In total,4796 cases of atezolizumab ADEs reported in the American FAERS database from 2017 to 2019 were retrospectively analyzed.Results The top three ADEs were febrile neutropenia(3.7%),anemia(2.9%),and acute renal failure(2.3%).In addition,the incidence rates of some ADEs were significantly different according to sex and age.The systematic organ classification of atezolizumab ADEs involved 32 systems,among which the top three were blood and lymphatic system disorders(585 cases,12.2%),gastrointestinal disorders(433 cases,9.0%),and infections and infestations(401 cases,8.4%).The reporting odds ratio(ROR)method was used to detect the ADR signals of atezolizumab.The ROR(95%confidence interval)of the top ADE,febrile neutropenia,was 39.236(33.757–45.604).In addition,we found 121 cases of complications associated with immune-related ADEs.Conclusion The ADRs of atezolizumab reported in the FAERS database were consistent with those mentioned in the instructions for atezolizumab use,suggesting that atezolizumab has an acceptable and controllable drug effect.
文摘目的分析与探讨达托霉素所致药品不良反应的发生特点及规律,为临床合理用药提供参考。方法检索万方、知网、维普、Web of Science、PubMed等数据库,收集达托霉素所致药品不良反应的相关文献,并进行统计与分析。结果共检索到59篇达托霉素所致的药品不良反应案例报道,以男性患者为主(70.83%),平均年龄为(61.5±14.3)岁,中位年龄(四分位数范围)为61(53.0~70.2)岁,多数为中老年患者;达托霉素多用于治疗骨、关节感染(61.11%);用药后药品不良反应发生的时间跨度较大,累及呼吸系统的不良反应最为常见(46.11%),其中以嗜酸性粒细胞肺炎为主。结论临床应用达托霉素时,医护人员应警惕相关药品不良反应的发生,药师应针对性地加强用药监护及药品不良反应干预,确保患者用药安全。
